CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and launching products in China, the United States, and globally. CASI's product portfolio includes several therapeutics, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for multiple myeloma patients, along with CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. The company's primary revenue driver is the sales of EVOMELA, as it executes its strategy to become a leading biopharmaceutical player by leveraging its expertise in regulatory and commercial operations within the China market.
Top Stages
3 past transactions
Precision Autoimmune Therapeutics
Venture Round in 2022
Precision Autoimmune Therapeutics is a clinical-stage innovative drug development company focused on precision therapeutics for patients with autoimmune and inflammatory diseases.
Juventas
Series A in 2019
Juventas is a developer of innovative immune cell therapeutic drugs aimed at treating malignant hematological neoplasms, including leukemia and lymphoma. The company has had its first investigational new drug application for the cell therapeutic product CNCT19 accepted by the National Medical Products Administration. Juventas is committed to developing a comprehensive product pipeline that focuses on advancing immune cell therapies and accelerating innovation in this field, thereby providing effective treatment options for patients suffering from these serious conditions.
Miikana Therapeutics
Acquisition in 2006
Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs and also in-licenses pre-clinical and early clinical oncology drug candidates, aiming to enhance its therapeutic offerings. Through its focused approach, Miikana Therapeutics strives to advance potential treatments that address the complex challenges of cancer care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.